///Overactive Bladder Clinical Trial Seeks Men and Women Over 65

Overactive Bladder Clinical Trial Seeks Men and Women Over 65

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adults With Overactive Bladder (OAB)

The purpose of this study is to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
Men and women are welcome to participate. You must be over the age of 65 and have symptoms of wet overactive bladder (OAB) (urinary frequency and urgency with incontinence) for greater than or equal to 3 months prior to Screening. You must be willing and able to complete the micturition diary and questionnaires correctly.

You may not participate if:

  • You have ongoing symptoms suggestive of bladder outlet obstruction (BOO) or history of BOO that is currently not well controlled.
  • You have a Post-Void Residual Volume (PVR) greater than 150 mL.
  • You have neurogenic bladder or neurological dysfunction or injury which could affect the lower urinary tract or nerve supply.
  • You have significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the Investigator (for female subjects confirmed by a cough provocation test). Subjects with a history of stress incontinence that is currently treated (e.g. remote history of surgery for stress incontinence) may be included as long as they pass cough provocation test.
  • You have an indwelling catheter or practices intermittent self-catheterization.

Clinical trial centers are located throughout the USA

Click here to learn more about the study and view study locations! 


By | 2017-01-24T12:25:16+00:00 January 24th, 2017|Clinical Trials|Comments Off on Overactive Bladder Clinical Trial Seeks Men and Women Over 65

About the Author:

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). Jill currently serves on the Congressionally Directed Medical Research Panel (US Army) where she collaborates with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. With a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including the “Living with IC” video series currently on YouTube and the ICN Food List smartphone app! Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.